These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2346130)

  • 1. Delayed life-threatening pneumonitis secondary to procarbazine.
    Brooks BJ; Hendler NB; Alvarez S; Ancalmo N; Grinton SF
    Am J Clin Oncol; 1990 Jun; 13(3):244-6. PubMed ID: 2346130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute pneumonitis associated with MOPP chemotherapy of Hodgkin's disease.
    Cersosimo RJ; Licciardello JT; Matthews SJ; Bromer R; Hong WK
    Drug Intell Clin Pharm; 1984; 18(7-8):609-11. PubMed ID: 6101251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 4. [MOPP therapy of Hodgkin's disease previously treated with MOPP].
    Frau A; Montalar J
    Med Clin (Barc); 1985 May; 84(19):801. PubMed ID: 3839875
    [No Abstract]   [Full Text] [Related]  

  • 5. Gallium citrate Ga 67 accumulation in pulmonary lesions after chemotherapy (MOPP).
    Wells JD; Huskison WT; Davenport OL
    South Med J; 1986 Oct; 79(10):1293-6. PubMed ID: 3464101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients.
    Gobbi PG; Cavalli C; Rossi A; Bertoloni D; Galeone F; Pieresca C; Grignani E
    Haematologica; 1987; 72(6):523-8. PubMed ID: 3126109
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent issues in chemotherapy for Hodgkin's disease.
    Canellos GP
    Curr Opin Oncol; 1989 Oct; 1(1):29-31. PubMed ID: 2489946
    [No Abstract]   [Full Text] [Related]  

  • 10. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOPP/ABVD chemotherapy for advanced Hodgkin's disease.
    Glick JH; Tsiatis A
    Ann Intern Med; 1986 Jun; 104(6):876-8. PubMed ID: 2422998
    [No Abstract]   [Full Text] [Related]  

  • 13. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
    Klimo P; Connors JM
    J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
    Fuller LM; Hagemeister FB
    Recent Results Cancer Res; 1989; 117():197-204. PubMed ID: 2602645
    [No Abstract]   [Full Text] [Related]  

  • 16. Semantics and the chemotherapy of Hodgkin's disease--resistance is not relapse: alternative chemotherapy lacks effectiveness for disease not totally responsive to initial MOPP treatment.
    Coleman M; Friedlander RJ
    Cancer Invest; 1988; 6(2):237-9. PubMed ID: 3288299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
    Fiacchini M; Lauria F; Mazza P; Cantore M; Gherlinzoni F; Tura S
    Haematologica; 1985; 70(2):148-54. PubMed ID: 3924778
    [No Abstract]   [Full Text] [Related]  

  • 19. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
    Constine LS
    J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.